Primary Hyperoxaluria - Pipeline Insight, 2024

Primary Hyperoxaluria - Pipeline Insight, 2024

DelveInsight’s, “Primary Hyperoxaluria – Pipeline Insight, 2024,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Primary Hyperoxaluria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Primary Hyperoxaluria Understanding

Primary Hyperoxaluria: Overview

Primary hyperoxaluria (PH) is a group of rare genetic metabolic disorders that are characterized by the accumulation of a substance known as oxalate in the kidneys and other organ systems of the body. Affected individuals lack functional levels of a specific enzyme that normally prevents the accumulation of oxalate. There are three main types of PH – PH types I, II, and III – differentiated by the specific enzyme that is deficient. In the kidneys, excess oxalate binds with calcium to form a hard compound (calcium oxalate) that is the main component of kidney and urinary stones. Common symptoms include the formation of stones throughout the urinary tract (urolithiasis) and kidneys (nephrolithiasis) and progressively increased levels of calcium in the kidneys (nephrocalcinosis). PH type I is caused by changes (mutations) in the AGXT gene. PH type II is caused by mutations in the GRHPR gene. PH type III is caused by mutations in the HOGA1 gene. A diagnosis of PH is based upon identification of characteristic symptoms (e.g. chronic stone formation), a detailed patient history, a thorough clinical evaluation and a variety of specialized tests. X-ray examinations can reveal the presence of kidney stones or calcium oxalate deposits in tissue. Computed tomography (CT) scanning, a specialized imaging technique, uses a computer and x-rays to create a film showing cross-sectional images of certain tissue structures such as kidney tissue. CT or MRI can detect the severity of systemic oxalosis by imaging the retina, heart, and bone in greater detail. Certain medications may be used to treat individuals with PH including potassium citrate, thiazides, magnesium, or orthophosphates. These medications in combination with water intake can further reduce the risk of calcium and oxalate crystallization but often do not entirely prevent stone formation or kidney failure.

""Primary Hyperoxaluria - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Primary Hyperoxaluria pipeline landscape is provided which includes the disease overview and Primary Hyperoxaluria treatment guidelines. The assessment part of the report embraces, in depth Primary Hyperoxaluria commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Primary Hyperoxaluria collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Primary Hyperoxaluria R&D. The therapies under development are focused on novel approaches to treat/improve Primary Hyperoxaluria.

Primary Hyperoxaluria Emerging Drugs Chapters

This segment of the Primary Hyperoxaluria report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Primary Hyperoxaluria Emerging Drugs

• Oxabact: OxThera

To address Primary Hyperoxaluria (PH), OxThera has taken a bacterial strain isolated from the human gut and developed a live biotherapeutic product candidate. Oxalobacter formigenes is an anaerobe, non-pathogenic bacterium which exclusively uses oxalate as the energy source. Administration of the bacteria at pharmacological doses to PH patients is hypothezised to promote active, incremental secretion of oxalate into the gut where it is subject to degradation and enteric elimination. This highly innovative approach reroutes oxalate elimination to the gut, thereby reducing the high oxalate burden on the kidneys. Oxabact is being evalauated in Phase III stage of development for the treatment of Primary Hyperoxaluria.

• DCR-PHXC: Dicerna Pharmaceuticals

Nedosiran (formerly referred to as DCR-PHXC) is the only RNAi drug candidate in development for primary hyperoxaluria (PH) types 1, 2 and 3 and is Dicerna’s most advanced product candidate utilizing the proprietary GalXC™ RNAi technology platform. Nedosiran is designed to inhibit the lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in a common pathway resulting in oxalate overproduction in patients with PH1, PH2 and PH3. Dicerna is evaluating the safety and efficacy of nedosiran in Phase III clinical trial in patients with all known forms of PH as part of its PHYOX clinical development program. In November 2014, Arbutus signed a licensing and collaboration agreement with Dicerna Pharmaceuticals, Inc., to utilize the proprietary LNP delivery technology exclusively in Dicerna’s primary hyperoxaluria type 1 (PH1) development program.

Further product details are provided in the report……..

Primary Hyperoxaluria: Therapeutic Assessment

This segment of the report provides insights about the different Primary Hyperoxaluria drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Primary Hyperoxaluria

There are approx. 8+ key companies which are developing the therapies for Primary Hyperoxaluria. The companies which have their Primary Hyperoxaluria drug candidates in the most advanced stage, i.e. Phase III include, OxThera.

• Phases

DelveInsight’s report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Primary Hyperoxaluria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Primary Hyperoxaluria: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Primary Hyperoxaluria therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Primary Hyperoxaluria drugs.

Primary Hyperoxaluria Report Insights

• Primary Hyperoxaluria Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Primary Hyperoxaluria Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Primary Hyperoxaluria drugs?
• How many Primary Hyperoxaluria drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Primary Hyperoxaluria?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Primary Hyperoxaluria therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Primary Hyperoxaluria and their status?
• What are the key designations that have been granted to the emerging drugs?